Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944565 · ClinicalTrials.gov registry record · Phase 2
Daratumumab in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02944565 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 28 participants.
The verdict
NCT02944565, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2017-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944565
The ClinicalTrials.gov registry entry for NCT02944565 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daratumumab is the first listed.
NCT02944565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02944565 about?
NCT02944565 is a clinical study titled "Daratumumab in Treating Patients With Multiple Myeloma". This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT02944565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-02-22. Estimated completion is 2017-07-20.
What interventions are being tested in trial NCT02944565?
The interventions under investigation include: Daratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02944565?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.